ANDREW GULBIS: Open Payments
NPI 1720216443 · TOMBALL, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,101 in 50 payments from 17 companies in 2025. Trend: 2023 $837 · 2024 $1,220 · 2025 $1,101
Food & beverage: $1,101
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $160 |
| Novo Nordisk Inc | 8 | $148 |
| HARMONY BIOSCIENCES LLC | 4 | $127 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $123 |
| ABBVIE INC. | 6 | $113 |
| GlaxoSmithKline, LLC. | 6 | $113 |
| Lilly USA, LLC | 3 | $56 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $50 |
| Antares Pharma, Inc. | 2 | $39 |
| CeQur Corporation | 1 | $33 |
Products named: BREZTRI, WAKIX, CAPLYTA, TRELEGY ELLIPTA, Ozempic, QULIPTA, XIFAXAN, XYOSTED.
Industry payments across TX — which companies pay providers there.
